# US 2012/0252907 A1 · Diagnostic methods and kit for detecting cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252907 A1
- Document ID: US20120252907A1
- Status: Published application
- Kind: A1
- Application number: 13/433,722
- Filed: 2012-03-29
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Indiana University Research and Technology Corporation
- Inventors: Harikrishna NAKSHATRI
- Web page: https://patentgrep.com/patent/US20120252907A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/57515: of the breast
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual.

## Claims

### Claim 1

An improved diagnostic screen for detecting and/or monitoring the progression of cancer, said method comprising
isolating a serum sample from a subject;
determining the concentration of a small microRNA, SNORD44 in said subject's sample;
determining the concentration of a breast cancer-associated microRNA in said subject's sample;
normalizing the concentration of said breast cancer-associated microRNA detected in said subject's sample and the concentrations of said breast cancer-associated microRNA present in samples from healthy individuals, using SNORD44 as a normalization control; and
comparing the normalized concentrations wherein a difference in the normalized concentration of said breast cancer-associated microRNA in said subject's sample relative to healthy individual's samples indicates the presence of cancer.

### Claim 2 (depends on 1)

The method of claim 1 wherein the breast cancer-associated microRNA is U6.

### Claim 3 (depends on 1)

The method of claim 1 wherein said comparing step uses a standard curve based on population data of said breast cancer-associated microRNA concentrations in healthy individuals relative to SNORD44 concentrations.

### Claim 4

A method of treating cancer, said method comprising the step of
administering an inhibitor of RNAP-III in an amount effective to modulate the activity of RNAP-III to control cancer cell growth and/or the secondary effects of cancer.

### Claim 5

A method of detecting cancer in a patient, said method comprising the steps of
determining the concentration of microRNA U6 in a serum sample obtained form said patient;
determining the concentration of microRNA SNORD44 in a serum sample obtained form said patient;
inputting said determined concentration values into a computer comprising programming for analyzing the concentration of U6 relative to population data established for healthy individuals and using detected SNORD44 levels as a normalization control, wherein said programming produces a conclusion regarding the probability of the patient having cancer.

### Claim 6 (depends on 1)

The method of claim 1 wherein said analyzing step uses a standard curve based on population data of said U6 microRNA concentrations in healthy individuals relative to SNORD44 concentrations

### Claim 7

A kit for detecting and normalizing the presence of a breast cancer-associated microRNA, said kit comprising
materials that can detect the presence of U6 microRNA; and
materials that can detect the presence of SNORD44 microRNA.

### Claim 8 (depends on 7)

The kit of claim 7 wherein the materials comprise a reverse transcriptase.

### Claim 9 (depends on 8)

The kit of claim 8 wherein the materials comprise PCR primers for amplifying the U6 microRNA and SNORD44 microRNA.

### Claim 10 (depends on 7)

The kit of claim 7 wherein the materials comprise labeled oligonucleotide probes.
